Recent literature8, 9, 10 indicates that while apoptosis induction remains a common chemotherapeutic action mechanism, primary apoptosis regulators, notably p53 and p16/CDKN2A, are often inactivated within tumour tissues, which can lead to resistance against such treatments. Here, CDKN2A is linked to neoplasm.